Activity of macrophages in tumors remain poorly defined
Patrick Hwu shared on X:
“The metabolic networks regulating the activity of macrophages in tumors remain poorly defined. Filippo Veglia, along with Moffitt’s Michael Vogelbaum, Paolo Rodriguez and other colleagues, reported that ER stress-driven glucose metabolism drives the immunoinhibitory potential of brain tumor macrophages, via histone lactylation.
Here’s a link to the full article.”
Authors: Alessandra De Leo, Alessio Ugolini, Xiaoqing Yu, Fabio Scirocchi, Delia Scocozza, Barbara Peixoto, Angelica Pace, Luca D’Angelo, James K.C. Liu, Arnold B. Etame, Aurelia Rughetti, Marianna Nuti, Antonio Santoro, Michael A. Vogelbaum, Jose R. Conejo-Garcia, Paulo C. Rodriguez, Filippo Veglia
Source: Patrick Hwu/X
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy.
He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.
Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research.
Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.